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The Centers for Disease Control
and Prevention (CDC) convened a
conference on March 12–13, 2003, in
Atlanta, Georgia, to discuss improv-
ing state-based surveillance of drug-
resistant  Streptococcus pneumoniae
(DRSP) and methicillin-resistant
Staphylococcus aureus (MRSA). The
Council of State and Territorial
Epidemiologists, the Association of
Public Health Laboratories, and CDC
co-sponsored the conference; 120 par-
ticipants from 38 states attended. The
conference was organized by the
Divisions of Healthcare Quality
Promotion and Bacterial and Mycotic
Diseases, National Center for
Infectious Diseases, CDC. Goals of
the meeting included 1) reviewing the
rationale for surveillance of DRSP
and MRSA, 2) presenting scientific
studies highlighting valid and mean-
ingful methods of performing state-
level surveillance, 3) sharing state-
level surveillance experiences, and 4)
identifying unmet needs of the state
health departments in performing
such surveillance.
The primary theme of the confer-
ence general sessions was the public
health impact of DRSP and MRSA
and the need for accurate surveillance
data to track and monitor resistance
trends.  S. pneumoniae is a major
cause of respiratory infections in the
United States. Since the early 1990s,
the prevalence of resistance to single
and multiple antibiotics has been
increasing in pneumococci.
Antimicrobial drug resistance in S.
pneumoniae can vary among popula-
tions and is influenced by local pre-
scribing practices and the prevalence
of resistant clones. Conference pre-
senters discussed the role of surveil-
lance in raising awareness of the
resistance problem and in monitoring
the effectiveness of prevention and
control programs. National- and state-
level epidemiologists discussed the
benefits of including state-level sur-
veillance data with appropriate antibi-
otic use programs designed to address
the antibiotic prescribing practices of
clinicians.  The potential for local sur-
veillance to provide information on
the impact of a new pneumococcal
vaccine for children was also exam-
ined; the vaccine has been shown to
reduce infections caused by resistance
strains 
Since the early 1990s, S. aureus
infections resistant to oxacillin
(MRSA) have increased steadily.
Several scientists reported two recent
changes in the epidemiology of
MRSA: its emergence in persons
without established risk factors and
the emergence of vancomycin-resist-
ant  S. aureus (VRSA). These new
developments underscore the need for
scientifically valid, yet financially
feasible, state-based surveillance that
will aid in understanding the changing
epidemiology of MRSAdisease. Such
understanding will allow effective
implementation of MRSA prevention
and control programs. Prevention pro-
grams will differ on the basis of which
populations are most affected (long-
term care, community, and hospice).
Current programs focus on reducing
cross-transmission through improved
hand hygiene and wound care. (More
information is available from: URL:
http://www.cdc.gov/ncidod/hip/Aresi
st/aresist.htm). 
Conference participants generally
agreed that a lack of resources for sur-
veillance has challenged state public
health agencies committed to moni-
toring emerging antimicrobial drug
resistance. A conclusion drawn from
conference sessions was that statically
sound methods of data collection that
capture valid, meaningful, and useful
data and meet the financial restric-
tions of state budgets are indicated.
Active, population-based surveil-
lance for collecting relevant isolates is
considered the standard criterion.
Unfortunately, this type of surveil-
lance is labor-intensive and costly,
making it an impractical choice for
many states. The challenges of isolate
collection, packaging and transport,
data collection, and analysis may
place an unacceptable workload on
laboratory and epidemiology person-
nel.
Epidemiologists from several state
health departments that have elected
to implement enhanced antimicrobial
drug-resistance surveillance programs
presented alternative surveillance
methods currently implemented in
their states. Several surveillance mod-
els and knowledge gained by state-
based epidemiologists provided key
insights into the challenges and bene-
fits of implementing enhanced sur-
veillance programs. 
Two methods frequently used by
states are sentinel (i.e., survey of sub-
set of laboratories) and antibiogram
(i.e., cumulative susceptibility data)
surveillance. Common difficulties
were identified with implementing
sentinel systems. Those difficulties
included logistical obstacles with iso-
late or data processing and communi-
cation breakdowns between laborato-
ry, epidemiology, and hospital infec-
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tion control personnel. Care must be
taken in selecting the numbers and
types of laboratories to participate in
the sentinel network States collecting
antibiograms from hospitals and state
laboratories also face challenges,
including incompatible formatting of
drug-testing panels, the inconsistent
inclusion of duplicate or repeat iso-
lates, and inconsistent reporting of
denominator data. Solutions to these
problems commonly involve improv-
ing communication between clinical
microbiology laboratories and state
health departments, including labora-
tory input in decision making and pro-
viding feedback of data from the sys-
tem to participants. Guidance for
aggregating cumulative susceptibility
data (i.e., antibiograms) has been pub-
lished and can serve as a guide for
states and clinical microbiology labo-
ratories in conducting surveillance.
Also, having designated staff was
essential for successfully implement-
ing most programs. Presenters agreed
that the benefits of collecting local
data from these systems are substan-
tial and will assist prevention pro-
grams. 
Another aspect of surveillance
focuses on detecting rare events. Such
reports may include new changes in
susceptibility, new mechanisms of
resistance, susceptibility of unusual
pathogens, and unexpected sources of
resistant organisms. Establishing
good communication among person-
nel in health departments and clinical
laboratories is important for improv-
ing reporting of such events. 
Allocating resources for improved
surveillance is considered a practical
and responsive step for states interest-
ed in tracking local resistant trends.
Local data are important for raising
public awareness, establishing
resources and prevention activities,
developing and informing treatment
guidelines, monitoring trends, and
motivating behavior change among
clinicians.
This meeting and ongoing efforts
to study and validate surveillance
methods will assist local health
authorities in making decisions pro-
grams to monitor antimicrobial drug
resistance. The 2-day conference pro-
vided an opportunity to initiate an
exchange of current practices and
knowledge gained among states and
territories. This process marks the
first phase in building networks that
may potentially enhance training
resources, provide guidance for pro-
gram development, and identify fur-
ther technical assistance needed from
CDC. 
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